Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill quiet the spinning of vertigo?

NCT ID NCT04674735

Symptom relief Sponsor: Apsen Farmaceutica S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

Researchers are testing an experimental oral tablet called APSLXR in people with Meniere's disease or vertigo of vestibular origin. The main goal is to check whether the drug is safe when taken once a day for 60 days. A small group will also have blood tests to see how the body processes the drug. This phase 1 trial focuses on safety, not yet on whether the drug stops vertigo attacks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
APSLXR, an oral tablet taken once daily for 60 days
What this could lead to
If APSLXR proves safe, it could become a new treatment option to reduce vertigo attacks in people with Meniere's disease or other vestibular disorders.
What could go wrong
This is an early phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to show benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Expected to start

Jan 2023

An estimate. Start dates often move.

Expected to finish

Jun 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Meniere's Disease or Vertigo of Vestibular Origin; * Voluntarily consent to participate in the study; Exclusion Criteria: * Female patients who are pregnant or breastfeeding; * Participants presenting uncontroled systolic hipertension (\>140/90 mmHg); * Participants presenting uncontroled diabetes (blood glucose \>200 mg/dL).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meniere disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meniere disease peripheral vertigo Vertigo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meniere disease Vertigo Vertigo vestibular

More trials for these conditions

Other studies related to the condition(s) this trial covers.